Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Last updated: April 30, 2024
Sponsor: Qualigen Theraputics, Inc.
Overall Status: Active - Recruiting

Phase

1

Condition

Neoplasms

Neuroblastoma

Treatment

QN-302

Clinical Study ID

NCT06086522
302P1V01
  • Ages > 18
  • All Genders

Study Summary

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer).

Main questions:

  • What does the study drug do to human body (Pharmacodynamics [='PD'])

  • What does the body do to study drug (how processed in body (Pharmacokinetics [='PK']) - Safety

Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with histologically confirmed locally advanced or metastatic solidcarcinomas, who have had tumor progression after receiving all standard of caretherapies or for which there is no approved therapy 2. Evaluable or measurable diseaseby RECIST 1.1

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 54
Treatment Group(s): 1
Primary Treatment: QN-302
Phase: 1
Study Start date:
November 01, 2023
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • HonorHealth

    Scottsdale, Arizona 85251
    United States

    Active - Recruiting

  • Yale

    New Haven, Connecticut 06520
    United States

    Site Not Available

  • START Midwest

    Grand Rapids, Michigan 49546
    United States

    Active - Recruiting

  • MD Anderson Cancer Center

    Houston, Texas 77002
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.